期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 14, 期 9, 页码 992-999出版社
WILEY
DOI: 10.1093/eurjhf/hfs092
关键词
Heart failure; Immune system; Prognosis
资金
- AstraZeneca
- Societa Prodotti Antibiotici (SPA, Italy)
- Pfizer
- Sigma Tau
- European Commission [HEALTH-F4-2008-202156 TOLER-AGE]
- European Research Council-Advanced Grant (project HIIS)
- Fondazione CARIPLO (Ricerca Scientifica e Trasferimento Tecnologico) [2009-2582]
- Regione Lombardia (Ricerca Indipendente in Ambito Oncologico, Cardiocerebrovascolare ed Intensivistico, and 'Progetto Ricerca Indipendente 2010: Caratterizzazione della pentraxina lunga PTX3 come biomarcatore in patologia cardiovascolare')
- Roche Diagnostics
Pentraxin-3 (PTX3) is a component of the humoral arm of innate immunity which can regulate inflammatory processes. Since the role of inflammation in the progression of chronic heart failure (HF) is debated, we investigated the prognostic value of PTX3 and the effect of a statin in two large populations of patients with HF. Plasma levels of PTX3 were measured at randomization and after 3 months in 1457 patients enrolled in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) and 1233 patients enrolled in the GISSI-Heart Failure trial (GISSI-HF). The relationships between baseline PTX3 levels or their changes over time and mortality were evaluated with multivariable Cox proportional hazard models including clinical factors, high sensitivity C-reactive protein (hsCRP), and N-terminal pro brain natriuretic peptide (NT-proBNP). PTX3 concentration [median (Q1Q3) 5.34 (3.557.64) ng/mL, n 2690] was higher in females, in older patients, and those with lower body mass index. Baseline elevated PTX3 was associated with a higher risk of all-cause mortality [759 events, hazard ratio (HR) for 1 SD increase 1.20, 95 confidence interval (CI) 1.121.30, P 0.0001], cardiovascular mortality (587 events, HR 1.27, 95 CI 1.171.38, P 0.0001), or hospitalization for worsening HF (720 events, HR 1.21, 95 CI 1.121.30, P 0.0001), and marginally improved discrimination. Three-month changes in PTX3 were associated with fatal events after adjustment for hsCRP or NT-proBNP. Rosuvastatin lowered hsCRP levels but significantly raised PTX3. In two independent clinical trials that enrolled patients with chronic HF, PTX3 was consistently associated with outcomes. The opposite effects of a statin on hsCRP and PTX3 call for further investigation. NCT00336336 (GISSI-HF), NCT00206310 (CORONA).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据